Q1 net income $91.2M on warrant gain; cash $466M; FDA grants COMP360 rolling NDA submission

COMPASS Pathways plc

2026-Q1 EPS reported -$0.30

FDA granted Compass NDA rolling submission for COMP360 in TRD based on positive Phase 3 data; CNPV awarded.
Net income $91.2M ($0.71 basic EPS) vs net loss $17.9M in Q1 2025; non-cash warrant gain of $130.9M.
Cash $466.0M at Mar 31 2026 (from $149.6M at Dec 31 2025); debt $50.5M (from $31.6M).
R&D expenses $26.5M (down from $30.9M); G&A $16.4M (down from $18.7M).
Final NDA submission on track for Q4 2026; 26-week COMP006 data expected early Q3 2026.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001816590-26-000043

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.